logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Cancer and Palliative Care

Results

Drugs

November 2020

Olaparib in addition to abiraterone for metastatic castration-resistant prostate cancer – First line

Olaparib is administered orally in tablet form and can lead to cancer cell death by blocking DNA repair by an enzyme (protein) called PARP. By blocking PARP enzymes, the damaged DNA in cancer cells cannot be repaired, and the cells die. Abiraterone works by stopping the body making testosterone which subsequently stops the cancer growing. If licensed, this combination would provide a first-line treatment for men with mCRPC.

Drugs

November 2020

Polatuzumab vedotin in addition to R-CHP for diffuse large B-cell lymphoma – first line

Polatuzumab vedotin is a first-in-class drug specifically developed for the treatment of cancers that affect the blood and lymph system. It is an antibody that binds to CD79b, which is a protein on the surface of cancerous B-cells. It is administered as an intravenous infusion, absorbed by the cancer cells and the chemotherapy agent linked to the antibody releases inside the cancer cells, stops them from dividing and kills them. If licenced polatuzumab vedotin in addition to R-CHP would offer an additional treatment option for patients with untreated DLBCL.

Drugs

October 2020

Durvalumab in addition to platinum based chemoradiation therapy for treating non-small-cell lung cancer

Durvalumab is given by intravenous infusion and works by blocking an immune protein called programmed cell death ligand-1 (PD-L1). PD-L1 expression enables cancer cells to avoid recognition by the immune system. By blocking PD-L1, durvalumab allows the immune system to recognise and target the cancer cells. Addition of durvalumab to the current CRT treatment is thought to be more effective and improve overall survival rates compared to CRT alone. If licenced, durvalumab in addition to CRT may provide an additional treatment option for patients with unresectable, locally advanced NSCLC.

Drugs

October 2020

Lisocabtagene maraleucel for transplant-eligible and ineligible, relapsed or refractory, aggressive B-cell non-Hodgkin lymphoma – second-line

Lisocabtagene maraleucel is administered intravenously. It contains the patient’s white blood cells (T-cells) that have been modified genetically in the laboratory so that they make a protein called chimeric antigen receptor (CAR). The CAR T-cells attach to a particular protein called CD19 on the surface of cancer cells resulting in the death of these cells. If licensed, lisocabtagene maraleucel will offer a treatment option for adult patients with high-risk, relapsed or refractory aggressive B-cell NHL.

Drugs

October 2020

Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant

Atezolizumab is a type of protein called an antibody, which can bind to a protein called programmed death-ligand 1 (PD-L1) to prevent it from interacting with its target (PD-1). Thus, helping immune cells kill cancer cells and is used to treat many different types of cancer that express PD-L1. If licensed, atezolizumab would offer a neoadjuvant and adjuvant treatment option for patients with stage II, IIIA, or select IIIB NSCLC.

Drugs

October 2020

Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line

Ipatasertib is an oral, highly specific medicine designed to target and bind to all three forms of protein called AKT. By binding to AKT, ipatasertib blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. If licensed, ipatasertib in addition to abiraterone and prednisone will provide a new regimen for mCRPC.

Drugs

October 2020

Olaparib for BRCA mutated and high risk HER2 negative breast cancer – adjuvant therapy

Olaparib is in clinical development for the adjuvant treatment of adults who are breast cancer type 1 and type 2 susceptibility protein (BRCA) mutant and human epidermal growth factor receptor 2 (HER2)-negative and have completed local treatment and (neo)-adjuvant chemotherapy. BRCA1 and BRCA2 are proteins that help repair damaged DNA.

Drugs

October 2020

CC-486 for maintenance therapy in acute myeloid leukaemia

CC-486 is a drug that can be incorporated into the genetic material of cells instead of their natural building-block, cytidine. It is thought to work by altering the way the cell turns genes on and off and interfering with the production of new RNA and DNA, leading to the death of rapidly dividing cancer cells that are not responsive to normal growth control mechanism. Its oral route of administration avoids injection-site reactions and may enhance patient convenience. The benefits of extended CC-486 dosing and long‐term treatment are likely related to the impact on hypomethylation, potentially enhancing clinical activity of the drug by increasing exposure to cycling malignant cells. If licensed, CC-486 will provide an additional maintenance therapy options for older AML patients who achieved CR or CRi following IC and who are not candidates for or choose not to proceed to HSCT.

Drugs

September 2020

Liposomal cytarabine-daunorubicin for treating relapsed or refractory acute myeloid leukaemia in paediatric patients.

Liposomal cytarabine-daunorubicin is made up of the chemotherapy drugs daunorubicin and cytarabine contained within fat-based particles called liposomes. Liposomal cytarabinedaunorubicin is delivered by intravenous infusion and provides controlled release of daunorubicin and cytarabine. Daunorubicin works by interrupting the copying of DNA which is necessary for cancer cell growth and cytarabine works by inhibiting DNA production to kill cancerous cells. If licenced, liposomal cytarabine-daunorubicin may offer an additional treatment option for paediatric patients with relapsed or refractory AML.

Drugs

September 2020

Bintrafusp alfa for locally advanced or metastatic biliary tract cancer – second-line

Bintrafusp alfa, delivered via intravenous injection, is a novel bi-functional fusion protein that is composed of an antibody fused with a receptor. Chemotherapy aims to kill cancer cells by directly attacking them, whereas bintrafusp alfa works twofold by preventing cancer from being resistant to a patient’s immune system and stopping cancer cells from growing.

Get Alerts